This presentation offers an educational overview of next-generation sequencing (NGS) testing for hematologic malignancies, specifically myeloid disorders and multiple myeloma.
- Compare/Contrast usefulness of NGS testing vs. stand-alone single-gene assays.
- Identify recognized testing recommendations—World Health Organization and National Comprehensive Cancer Network.
- Develop cost-effective and clinically relevant algorithms for testing—diagnostic vs. follow-up testing.
This webinar is designed for any provider who treats patients with hematologic malignancies (e.g., oncologists, hematologists, and physician assistants), pathologists, hematopathologists, cytogeneticists, laboratory directors, genetic counselors, and laboratory technologists and support staff.